Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Clinical trial NCT03471351 · TERMINATED
Trial details
- NCT number
- NCT03471351
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-18
- Primary completion
- 2019-02-13
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.